<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 1997
CERUS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 0-21937 68-0262011
(State of jurisdiction) (Commission File No.) (IRS Employer
Identification No.)
2525 Stanwell Drive, Suite 300
Concord, CA 94520
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (510) 603-9071
<PAGE> 2
Item 5. Other Events
On February 19, 1997, Cerus Corporation filed a Prospectus Supplement to
the Prospectus dated January 30, 1997 with the Securities and Exchange
Commission discussing the results of a February 13,1997 meeting with the
United States Food and Drug Administration, which is filed herewith as
Exhibit 99.1 and incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits.
Exhibit
Number Description
- ------- --------------
99.1 Prospectus Supplement, dated February 19, 1997.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Cerus Corporation
Dated: February 19, 1997 By: /s/ David S. Clayton
--------------------------
David S. Clayton
Vice President, Finance and
Chief Financial Officer
<PAGE> 4
EXHIBIT INDEX
Exhibit
Number Description
- ------- --------------
99.1 Prospectus Supplement, dated February 19, 1997.
<PAGE> 1
EXHIBIT 99.1
PROSPECTUS SUPPLEMENT
(To Prospectus Dated January 30, 1997)
2,000,000 Shares
CERUS
COMMON STOCK
------------------------
The purpose of this Prospectus Supplement is to provide supplemental
information regarding Cerus Corporation (the "Company") in connection with the
Company's offering of Shares of its Common Stock as described in the Company's
Prospectus dated January 30, 1997 pursuant to which such offering is being made.
Capitalized terms defined in the Prospectus are used in this Prospectus
Supplement as defined in the Prospectus. The information included in this
Prospectus Supplement should be read in conjunction with the Prospectus.
------------------------
As a result of a February 13, 1997 meeting with FDA staff, the Company has
elected to conduct a pilot study before the U.S. commencement of its Phase 3
clinical trial of its proprietary platelet pathogen inactivation system. The
purpose of this additional study is to evaluate the safety and efficacy of
platelets treated with the Company's pathogen inactivation system in a small
group of patients before conducting the larger Phase 3 patient study. To date,
the Company's clinical trials have been conducted only in healthy subjects.
As a result of this additional small-scale trial, the Company believes that
the U.S. Phase 3 clinical trial will not begin before late 1997. The Company had
previously anticipated beginning the Phase 3 trial in mid-1997. The Company is
currently working with its development and marketing collaborator, Baxter, to
design and submit to the FDA a protocol for the proposed pilot study. The
Company expects to make a further announcement when such protocol is finalized.
The Company's current estimate of the scope of the proposed pilot study and
the timing of the commencement of the U.S. Phase 3 clinical trial are
forward-looking statements that involve risks and uncertainties. The actual
scope and timing could differ materially from the above forward-looking
statements as a result of certain factors, including the Company's ability to
begin and successfully complete the proposed pilot study in a timely fashion and
the response of the FDA to the design of the pilot and Phase 3 studies, as well
as other factors discussed in the Company's Prospectus dated January 30, 1997.
See "Risk Factors," "Business -- Products Under Development" and "-- Government
Regulation."
------------------------
February 19, 1997
